Q-omics provides the consensus-scored PIM1 profile across patient tissues and cancer cell-line models. PIM1 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, PIM1 is differentially expressed in 9, with the highest sampling consensus in BRCA. Additionally, PIM1 RNA expression shows 16,813 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight THCA, BRCA, and ACC as cancer lineages where PIM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PIM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PIM1 survival associations across molecular data types. PIM1 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PIM1 RNA expression–survival associations across cancer types. High PIM1 expression shows unfavorable associations in THCA, LGG, KIRC, UCEC and COAD, but favorable associations in SKCM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify THCA as the clearest survival context for PIM1 RNA expression.
This table summarizes PIM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in BRCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PIM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PIM1 shows lower tumor expression in BRCA, BLCA, UCEC and THCA and higher tumor expression in KIRP and KICH. The BRCA box plot shows higher PIM1 RNA expression in normal versus tumor tissue (log2 FC = −0.507, t-test p < 0.001).
This table shows molecular features associated with PIM1 in patient tissues and cancer cell lines. In patient samples, PIM1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PIM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
